Sargent Bickham Lagudis’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Sargent Bickham Lagudis’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-17	Closed	-$1K	–	808
2018 Q1	$1K	Hold	17	–	–	﹤0.01%	746
2017 Q4	$1K	Hold	17	–	–	﹤0.01%	774
2017 Q3	$1K	Hold	17	–	–	﹤0.01%	795
2017 Q2	$1K	Hold	17	–	–	﹤0.01%	756
2017 Q1	$1K	Hold	17	–	–	﹤0.01%	733
2016 Q4	$1K	Hold	17	–	–	﹤0.01%	694
2016 Q3	$1K	Hold	17	–	–	﹤0.01%	704
2016 Q2	$1K	Hold	17	–	–	﹤0.01%	693
2016 Q1	$1K	Buy	+17	New	+$720	﹤0.01%	708

Other funds holding XPH

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JGGDR

JGP Global Gestao de Recursos Rio De Janeiro, Brazil $45.3M AUM 42.75% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Sargent Bickham Lagudis's XPH Position: Q2 2018 in Review

Sargent Bickham Lagudis sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q2 2018, closing a stake of 17 shares — an estimated $1K sold.

Sargent Bickham Lagudis first reported a position in XPH in Q1 2016 and held it in 9 quarters. The position peaked at $1K in Q1 2018. 70 funds tracked by Wall St. Rank hold XPH as of Q2 2018.

Sargent Bickham Lagudis reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q2 2018 after selling out during the quarter.
Sargent Bickham Lagudis sold 17 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2018, an estimated $1K.
Sargent Bickham Lagudis first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2016 and held it in 9 quarters.
Sargent Bickham Lagudis's State Street SPDR S&P Pharmaceuticals ETF position peaked at $1K in Q1 2018.
70 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2018.

Based on Sargent Bickham Lagudis's 13F filing for Q2 2018, filed 13 Sep 2021.